Can angiogenesis inhibitor therapy cause changes in imaging features of hepatic hemangioma- Initial study [PDF]
Frontiers in Oncology, 2023 BackgroundTo observe whether anti-angiogenesis therapy can induce changes in size and enhancement characteristics of hepatic hemangioma.Method133 patients with hepatic hemangioma lesions were analyzed and classified into a Bevacizumab group (n=65) and ...
Tang Liu +3 more
doaj +2 more sources
Thalidomide is an inhibitor of angiogenesis. [PDF]
Proceedings of the National Academy of Sciences, 1994 Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans. We have demonstrated that orally administered thalidomide is an inhibitor of angiogenesis induced by basic fibroblast growth factor in a rabbit cornea micropocket assay ...
R. D'Amato +3 more
semanticscholar +5 more sources
First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China [PDF]
Cancer Medicine, 2023 Background Currently, survival benefit of immunotherapy in advanced non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) is controversial, though it generally indicates poor response and activity.
Guangjian Yang +10 more
doaj +2 more sources
Case report: Pathological complete response to perioperative treatment of radiotherapy combined with angiogenesis inhibitor in a patient with pleomorphic liposarcoma [PDF]
Frontiers in Oncology, 2023 BackgroundLiposarcomas (LPS) are mesenchymal malignancies with four principal subtypes presenting distinct molecular and clinical features. Pleomorphic liposarcoma (PLPS) is one of the rarest and most aggressive subtypes of LPS.
Chenlu Zhang +11 more
doaj +2 more sources
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation [PDF]
Cancer Medicine, 2021 Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are currently the primary treatment option for patients with EGFR‐mutant non‐small cell lung cancer (NSCLC).
Hiroaki Kodama +15 more
doaj +2 more sources
Editorial: Angiogenesis and Angiogenesis Inhibitors in Oral Cancer [PDF]
Frontiers in Oral Health, 2021 Non peer ...
Abdelhakim Salem +5 more
doaj +4 more sources
Endogenous inhibitors of angiogenesis [PDF]
Journal of Cell Science, 2001 In the course of embryonic development, during some normal physiological processes in the adult, such as the female reproductive cycle, and also in a variety of pathologies, including tumour growth, new blood vessels develop from the pre-existing vascular network through endothelial cell sprouting,
Christiana Ruhrberg
openalex +6 more sources
Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer. [PDF]
Cell Death Dis, 2020 Lei X +8 more
europepmc +2 more sources
Therapeutic Response of Soft Tissue Sarcoma With Novel SS18-POU5F1 Fusion: A Case Report
Frontiers in Oncology, 2021 A novel SS18-POU5F1 fusion gene was recently reported in soft tissue sarcoma occurring in three adolescent and young adult patients. Herein, we firstly reported the treatment response of SS18-POU5F1 sarcoma to immune checkpoint inhibitor, angiogenesis ...
Zengjun Liu +3 more
doaj +1 more source
Scientific Reports, 2021 In order to identify more effective therapy for recalcitrant osteosarcoma, we evaluated the efficacy of an mTOR-VEGFR inhibitor combination on tumor growth in a unique osteosarcoma patient-derived orthotopic xenograft (PDOX) mouse model derived from the ...
Hiromichi Oshiro +7 more
doaj +1 more source